NHS England Backs Biosimilar-To-Biosimilar Switching As It Counts Adalimumab Savings
Switching between biosimilars does not appear to raise safety concerns, according to NHS England, which is anticipating more than £300m in annual savings from biosimilar competition on adalimumab.
You may also be interested in...
Responding to UK government statements on the country’s future approach to trade deals with non-EU nations, the BGMA has insisted that there must be no changes to patent and exclusivity provisions that would block market entry for generic and biosimilar medicines.
A UK TV program revealed secret meetings between drug makers and British civil servants but for its part, the American Pharmaceutical Group says it has had no discussions
A KPMG report commissioned by Medicines for Europe finds that nine ‘key ingredients’ could maximize savings for generic and biosimilar medicines in European hospitals.